Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

617 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intensive single-agent mitoxantrone for metastatic breast cancer.
Shpall EJ, Jones RB, Holland JF, Bhardwaj S, Paciucci PA, Wilfinger CL, Strashun A. Shpall EJ, et al. Among authors: holland jf. J Natl Cancer Inst. 1988 Apr 6;80(3):204-8. doi: 10.1093/jnci/80.3.204. J Natl Cancer Inst. 1988. PMID: 3279218 Clinical Trial.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Citron ML, et al. Among authors: holland jf. J Clin Oncol. 2003 Apr 15;21(8):1431-9. doi: 10.1200/JCO.2003.09.081. Epub 2003 Feb 13. J Clin Oncol. 2003. PMID: 12668651 Clinical Trial.
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L. Henderson IC, et al. Among authors: holland jf. J Clin Oncol. 2003 Mar 15;21(6):976-83. doi: 10.1200/JCO.2003.02.063. J Clin Oncol. 2003. PMID: 12637460 Clinical Trial.
Chemotherapy of metastatic cancer in bone.
Bhardwaj S, Holland JF. Bhardwaj S, et al. Among authors: holland jf. Clin Orthop Relat Res. 1982 Sep;(169):28-37. Clin Orthop Relat Res. 1982. PMID: 7049490 Review.
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Weiss RB, Holland JF. Perloff M, et al. Among authors: holland jf. J Clin Oncol. 1996 May;14(5):1589-98. doi: 10.1200/JCO.1996.14.5.1589. J Clin Oncol. 1996. PMID: 8622076 Clinical Trial.
A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
Gottlieb AJ, Anderson JR, Ginsberg SJ, Bloomfield CD, Norton L, Barcos M, Peterson BA, Nissen N, Henderson ES, Holland JF. Gottlieb AJ, et al. Among authors: holland jf. Cancer. 1990 Nov 1;66(9):1888-96. doi: 10.1002/1097-0142(19901101)66:9<1888::aid-cncr2820660906>3.0.co;2-k. Cancer. 1990. PMID: 1699653 Clinical Trial.
617 results